《中国康复理论与实践》

中国康复理论与实践 >

2019 , Vol. 25 >Issue 4: 493 - 496

DOI: https://doi.org/10.3969/j.issn.1006-9771.2019.04.023

康复管理

植入式骶神经刺激系统临床试验技术审评要求

  • 张宇晶 ,
  • 廖利民 ,
  • 李卫 ,
  • 阎小妍 ,
  • 刘晓燕 ,
  • 许伟
展开
  • 1.国家药品监督管理局医疗器械技术审评中心，北京市 100081
    2.中国康复研究中心北京博爱医院，北京市 100068
    3.国家心血管病中心中国医学科学院阜外医院医学研究统计中心，北京市 100037
    4.北京大学临床研究所,北京市 100191
张宇晶(1975-)，女，汉族，黑龙江大庆市人，硕士研究生，高级工程师，主要研究方向：有源医疗器械技术审评研究。

收稿日期: 2019-01-30

  修回日期: 2019-03-07

  网络出版日期: 2019-04-24

收起

Requirements of Technical Review for Clinical Trial for Implantable Sacral Nerve Stimulation System

  • ZHANG Yu-jing ,
  • LIAO Li-min ,
  • LI Wei ,
  • YAN Xiao-yan ,
  • LIU Xiao-yan ,
  • XU Wei
Expand
  • 1.Center For Medical Device Evaluation, National Medical Products Administration, Beijing 100081, China
    2.China Rehabilitation Research Center, Beijing 100068, China
    3.Medical Research & Biometrics Center, National Center for Cardiovascular Diseases, Chinese Academy of Medical Diseases, Fuwai Hospital, Beijing 100037, China
    4.Peking University Clinical Research Institute, Beijing 100191, China

Received date: 2019-01-30

  Revised date: 2019-03-07

  Online published: 2019-04-24

Fold

摘要

在植入式骶神经刺激系统临床试验的技术审评中，应主要关注以下方面：临床试验基本原则、临床试验医疗机构要求和临床试验方案设计要素。

关键词： 植入式骶神经刺激系统; 临床试验; 技术审评

本文引用格式

张宇晶 , 廖利民 , 李卫 , 阎小妍 , 刘晓燕 , 许伟 . 植入式骶神经刺激系统临床试验技术审评要求[J]. 中国康复理论与实践, 2019 , 25(4) : 493 -496 . DOI: 10.3969/j.issn.1006-9771.2019.04.023

Abstract

The technical review for clinical trials of implantable sacral nerve stimulation system needs to focus on the basic principles of trials, clinical institutition and design elements of clinical trial protocols.

Key words： implantable sacral nerve stimulation system; clinical trail; technical review

参考文献

[1] 袁媛,姜长青,陈玥,等. 神经调控技术的发展与展望[J]. 生命科学仪器, 2018, 16(纪念刊): 20-28.
[2] GoldmanH B, LloydJ C, NoblettK L, et al. International Continence Society Best Practice Statement for Use of Sacral Neuro-Modulation [J]. Neurourol Urodyn, 2018, 37(5): 1823-1848.
[3] OerlemansD J A J. Evolution of neuromodulation for lower urinary tract dysfunction: past, present and future [M/OL]. 2017. https://www.researchgate.net/publication/315796765
[4] 中华人民共和国国务院. 医疗器械监督管理条例[EB/OL]. (2017-05-04). http://samr.cfda.gov.cn/WS01/CL0784/237491.html.
[5] 国家食品药品监督管理总局. 医疗器械注册管理办法[EB/OL]. (2014-07-30). http://samr.cfda.gov.cn/WS01/CL0053/103756.html.
[6] 食品药品监管总局,国家卫生计生委. 医疗器械临床试验质量管理规范[EB/OL]. (2016-03-01). http://samr.cfda.gov.cn/WS01/CL0053/148101.html.
[7] 国家食品药品监督管理总局. 国家食品药品监督管理总局关于医疗器械临床试验备案有关事宜的公告[EB/OL]. (2015-07-03). http://samr.cfda.gov.cn/WS01/CL0087/123460.html.
[8] 食品药品监管总局,国家卫生计生委. 医疗器械临床试验机构条件和备案管理办法[EB/OL]. (2017-11-15). http://samr.cfda.gov.cn/WS01/CL0050/217368.html.
[9] 食品药品监督管理总局. 医疗器械临床试验设计指导原则[EB/OL]. (2018-01-04). http://samr.cfda.gov.cn/WS01/CL0087/221976.html.
[10] FDA. Guidance for industry and FDA staff－clinical investigations of devices indicated for the treatment of urinary incontinence [EB/OL].　(2011-03-08).　https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070852.htm.
[11] 张家振,刘斌,翟豹,等. 人工髋关节假体临床试验设计探讨[J]. 中国医疗器械杂志, 2018, 42(4): 262-264.
[12] BlokB, van KerrebroeckP, de WachterS, et al. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder [J]. Neurourol Urodyn, 2018, 37(S2): S9-S16.
[13] SiegelS, NoblettK, MangelJ, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder [J]. Neurourol Urodyn, 2015, 34(3): 224-230.
[14] NoblettK, SiegelS, MangelJ, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder [J]. Neurourol Urodyn, 2016, 35(2): 246-251.
[15] SiegelS, NoblettK, MangelJ, et al. Three-year follow-up results of a prospective,multicenter study in overactive bladder subjects treated with sacral neuromodulation [J]. Urology, 2016, 94: 57-63.
[16] NoblettK, BergK C, KanF, et al. Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients [J]. Neurourol Urodyn, 2018, 37(5): 1667-1671.
[17] AbramsP, AnderssonK E, BirderL, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse, and Fecal Incontinence [J]. Neurourol Urodyn, 2010, 29(1): 213-240.
[18] 食品药品监督管理总局. 膀胱过度活动症药物临试验指导原则[EB/OL]. (2017-12-25). http://samr.cfda.gov.cn/WS01/CL0087/221406.html.
[19] 骶神经调控术临床应用专家共识编写组. 骶神经调控术临床应用中国专家共识再版[J]. 中华泌尿外科杂志, 2018, 39(11): 801-804.
[20] SiegelS, NoblettK, MangeJ, et al. Five-year followup results of a prospective, mulicenter study of patients with overactive bladder treated with sacral neuromodulation [J]. J Urol, 2018, 199(1): 229-236.
[21] FDA. Guidance for industry and FDA staff－balancing premarket and postmarket data collection for devices subject to premarket approval [EB/OL]. (2015-04-13). https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm393994.pdf.
[22] 食品药品监督管理总局. 药物临床试验的一般考虑指导原则[EB/OL]. (2017-01-18). http://samr.cfda.gov.cn/WS01/CL0087/168752.html.
[23] 食品药品监督管理总局. 药物临床试验的生物统计学指导原则[EB/OL]. (2016-06-01). http://samr.cfda.gov.cn/WS01/CL0087/154780.html.
[24] 食品药品监管总局. 持续葡萄糖监测系统注册技术审查指导原则[EB/OL]. (2018-03-16). http://samr.cfda.gov.cn/WS01/CL0087/226783.html.
[25] 食品药品监管总局. 接受医疗器械境外临床试验数据技术指导原则[EB/OL]. (2018-01-10). http://samr.cfda.gov.cn/WS01/CL0087/222385.html.
Options
文章导航

/

〈 〉